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Abstract
Cancer is a disease that starts in a localized organ or tissue and then grows out of control. 
Breast cancer is an important health problem as in the Western world; it is the second 
most frequent cause of cancer death in women (after lung cancer). The incidence rate, 
however, rises dramatically over the age of 50 years. This is may be due to several risk 
factors, such as family history, genetics, early menstruation, late menopause, and other 
factors, that have not yet been identified. The problems of breast diseases have prompted 
global governments to put constant efforts to increase patient's recovery level against this 
disease. Early and accurate detection with mass screening programs helps improves a 
woman's chances for successful treatment. It also minimizes pain, suffering, and anxiety 
that surround patients and their families. The current and the most cost-effective tech-
nique used for screening and diagnosis of breast cancer is X-ray mammography. It is the 
state-of-the-art for earlier detection to improve both prognosis and survival rate. This is 
may be due to its good availability, high sensitivity, and relatively low cost/patient. The 
goal of this chapter is to introduce the problems caused by breast cancer. Starting with 
an overview of the requirement for breast tumor imaging and the diagnostic techniques 
used for breast cancer assessment are briefly described, highlighting the advantages and 
disadvantages of each technique. In addition, the problems associated with a relatively 
new functional breast imaging technique namely scintimammography were introduced 
and discussed. The intention that the chapter provide the reader with sufficient back-
ground on the available diagnostic techniques of breast tumor imaging approach, as well 
as an overview of the literature.
Keywords: breast cancer detection, molecular imaging, scintimammography
1. Introduction
Most women experience breast changes in their life. This is due to normal growth and changes 
in hormone levels. However, lumps, bumps, breast pain, nipple discharges, or skin irritation 
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Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
are examples of breast problems that have similar symptoms. The vast majority of lesions 
and abnormalities occurs in the breast are not cancer but are far more frequent than malig-
nant ones [1–7]. Benign breast constitutes a heterogeneous group of lesions including various 
abnormalities, inflammatory lesions, epithelial and stromal proliferations, and neoplasms 
[3–5]. However, cancer is a disease that starts in a localized organ or tissue and then grows 
out of control. Breast cancer is an important health problem as it is the most common malig-
nancy in women in Western countries. It is the second most frequent cause of cancer death in 
women (after lung cancer) [8, 9]. The incidence rate, however, rises dramatically over the age 
of 50 years. This is may be due to several risk factors such as family history, genetics, early 
menstruation, late menopause medication, and other factors that have not yet been identified. 
The above problems have prompted global governments to put constant efforts to increase 
patient's recovery level against this disease. Early and accurate detection with mass screening 
programs helps improves a woman's chances for successful treatment. It also minimizes pain, 
suffering, and anxiety that surround patients and their families. The goal of this chapter is 
to introduce the problems caused by breast cancer, starting with the requirements for breast 
imaging, an overview of the methods for diagnosing breast abnormalities with the focus on 
molecular imaging of the breast.
2. Requirements for breast imaging
The goal of breast evaluation is to classify findings as normal physiologic variations, clearly 
benign, or possibly malignant. The size, shape, and appearance of the female breast are 
not constant but undergo a number of changes during the lifetime of women. For instance, 
changes occur with pregnancy, breast feeding, and during the menstrual cycle. In addition, 
the age of the subject not only influences the shape but also parenchymal density of the breast. 
That is why young women tend to have dense breasts (more fibro-glandular tissue), creating 
a rounded appearance. On the other hand, postmenopausal women have breasts containing 
a large amount of fat. This makes the X-ray mammogram far more effective in older women 
as the fat content is more radio-translucent (appears darker) compared to glandular tissue 
(appears under-exposed) in younger women [10]. The above discussion suggests that both 
the shape and parenchymal density of the breast impose particular constraints on the choice 
of imaging modality. The imaging technique should be powerful for initial detection and 
subsequent follow-up of the diseases.
At present, no single technique was used for all cases of breast cancer detection without show-
ing certain clinical or technical limitations. This implies necessity to address the specific needs 
that can help for breast tumors imaging to overcome these limitations. For instance, breast 
compression often needed as it holds the breast still and enhances the spatial resolution. It 
also evens out the breast thickness and reduces scatter in X-ray or γ-ray imaging [11], thus 
increasing image sharpness. Moreover, it spreads out the tissue so that the overlying breast 
tissue will not obscure small abnormalities. Since the breast is an external organ and extends 
to the chest wall, it requires appropriate views to be obtained. For instance, in X-ray mam-
mography, a lateral (from the side) view of the breast allows separation of the chest wall from 
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lesions deep within the breast. On the other hand, in single photon γ-ray emission imaging, 
one needs to separate the breast from the heart by employing an appropriate prone (face 
down) position. However, it has been claimed that with prone imaging view, there is a pos-
sibility of missing a small low-intensity medial lesion because of attenuation. This implies that 
another image is needed but in the lateral view. In addition, shielding the camera from the 
background cardiac flux is very useful in tumor detection in terms of contrast and resolution.
3. Interpreting imaging test
The usefulness of diagnostic imaging tests, which is their ability to detect a patient or sub-
ject with disease or exclude a patient or subject without disease. In other words, the idea in 
using any diagnostic test is to be able to correctly diagnose the disease and easily interpret 
the results. The latter is achieved by calculating the probability that a patient has a disease. 
The diagnostic test performance is usually measured by calculating four important statisti-
cal parameters or terms. These are the test's sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) [12, 13]. Table 1 illustrates these parameters and 
their relationship. In breast tumor γ-ray imaging, these parameters are dependent on clinical 
history, biological factors such as size, site, or location, the type of the lesion, and patient’s 
age. The test parameters may also depend on the physical and the practical aspects as well as 
on the imaging technology parameters. Sensitivity and specificity are properties of a test that 
tell us how good the diagnostic test is at predicting the disease and whether it is to be used or 
not [12]. Sensitivity is the proportion of people with the disease who have a positive test for 
the disease [12]. Specificity is the proportion of people without the disease who test negative 
[12]. A high sensitivity test means that the test has a low rate of false-negatives and high speci-
ficity means that the test has a low rate of false-positives. In brief, the text here and Table 1 
simply provide a practical application, hence of what these concepts mean in clinical practice 
and how they can be used in practical settings to aid the diagnostic process.
In clinical practice, the decision to send patients for breast biopsies is arbitrary, i.e., there is no 
fixed test threshold. Instead, the decision is usually based on the needs of patients and clini-
cians for the different clinical situations. As a result, for any given image of a breast lesion, 
there is a kind of trade-off between the sensitivity and specificity, i.e., sensitivity can only 
Test outcome Condition as determined by “gold” standard
True False
Positive True positive False positive ⇒Positive predictive value
Negative False negative True negative ⇒Negative predictive value
⇓
Sensitivity
⇓
Specificity
Table 1. The main diagnostic test parameters [12, 13] demonstrating the practical application and the relationship of 
these four terms.
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increase by decreasing the specificity of a test. For instance, if the decision is to only select 
patients with extremely abnormal images to have breast biopsy, then the test will become 
extremely specific but not very sensitive. In this case, many patients falsely diagnosed as not 
having breast diseases or breast cancer. On the other hand, if the decision is to send patients 
with borderline abnormal images to have biopsy, the test will then become more sensitive but 
less specific. As a result, many patients who do not have breast cancer sent for an unneces-
sary biopsy, i.e., the diagnostic tests are useless. This sensitivity specificity trade-off of the 
diagnostic test is accurately illustrated by the analysis of the receiver operating characteristic 
(ROC) curve at each test threshold or cut-point. This curve is a plot of the true positive rate 
against the false positive rate for the different possible thresholds of the diagnostic test. The 
area under the ROC curve is a measure of test accuracy, i.e., how well the test separates or 
classifies the patient population into those with the abnormality and those without. An area 
of 1 represents excellent performance test and an area of 0.5 represents a fail test.
To know the probability that the imaging test is giving the correct diagnosis, the positive and 
negative predictive values are needed. The PPV of a test is the probability of a patient hav-
ing the disease following a positive test result [13]. The NPV is the probability of a person 
not having the disease following a negative test result [13]. These test performance measures 
are influenced by the probability of disease at any point in time of the total abnormality in 
the population tested [13]. The predictive values also vary as a function of disease preva-
lence and patient subpopulation. Thus, a combined measure of diagnostic performance, 
the likelihood ratio, is a clinically useful diagnostic test performance measure. Negative 
likelihood ratios measure the ability of the test to accurately rule out disease, and positive 
likelihood ratios measure the ability of the test to accurately detect disease. In summary, 
both sensitivity and specificity terms of a diagnostic test suffer from limitations in clinical 
practice, as they cannot estimate the probability of breast cancer in an individual patient. 
However, PPV and NPV help to overcome this problem, but they both vary according to 
disease prevalence and populations.
4. Diagnosis of breast disease
Breast lesion investigations may include self or clinical breast examination, X-ray mammog-
raphy, and biopsy. In addition, a variety of other efficient complementary imaging modalities 
provide additional information to achieve a definite breast diagnosis. The following subsec-
tions give an overview of the main diagnostic techniques used for breast tumor imaging.
4.1. X-ray mammography and screening
Mammography is a low energy (25–32 keV) X-ray examination of the soft tissues of the breast. 
It uses the variation in density between normal mammary features and abnormal tissue struc-
tures (lesion) to produce the image. The X-ray images are either captured on a film or directly 
stored on a digital computer. The former is one of the widely used current techniques based 
on screen-film technology. X-ray mammography considered the gold standard in breast 
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imaging as it is fast, available, and has a lower cost than other breast imaging techniques. It 
has two main applications: as a screening method in asymptomatic patients and as a diag-
nostic method in symptomatic populations. The former application is extremely important 
and its introduction in the past three decades has significantly reduced the mortality rate 
of breast cancer in many countries [14, 15]. This is because the screening services accurately 
detect micro-calcifications and nonpalpable soft tissue masses, which have been beyond other 
imaging methods, due to the high spatial resolution (∼50–100 μm). Normally, screening is 
achieved by exposing the breast to X-rays after gently compressed between two plates and 
then taking two views for each breast. A craniocaudal (imaging from above to below) and 
lateral views are generally taken. A lead grid is used to reduce scattering photons that reach 
the film. Diagnostic mammography evaluates the entire breast as well as characteristics of 
the mass. It is used for assessing the size of the lesion, for pre-surgical localization of suspi-
cious areas of breast, and in the guidance of needle biopsies. The reported sensitivity (the 
fraction of patients actually having the disease and correctly diagnosed as positive) in lesion 
detection varied between 69 and 90% [16] depending on the breast density. The specificity 
(the fraction of patients without the disease, correctly diagnosed as negative) is the major 
drawback of conventional mammography. A variation in specificity between 87 and 97% and 
a low positive predictive value as low as 15% has also been reported [17]. This ‘less than 
perfect’ performance may be due to several confounding factors, e.g., poor mammographic 
technique, observer error, the lesions are nonpalpable or at a cellular level, and/or the lesions 
are obscured by the normal breast tissues. The presence of scars or tissue distortion may hide 
true small tumors on the mammogram. Nevertheless, conventional mammography remains a 
valuable and cost-effective technique for breast tumor diagnosis. Over the last three decades, 
considerable efforts are carried out to improve the current screen-film mammographic tech-
nique. These improvements include image quality, acquisition techniques, and interpretation 
protocol in order to reduce some of the mammographic limitations [18].
The use of digital imaging in general radiography has increased rapidly in recent years. This 
has extended to mammographic imaging. “Digital mammography” (DM) is a possible cur-
rent direction in breast imaging compared to film-based conventional mammography. This 
is due to the presence of X-ray detector, which is considered the heart of DM. A number of 
technologies and several types of integrated digital detector system are in use nowadays. DM 
has the potential to improve contrast resolution compared with film-screen imaging. This 
is because DM detectors like other detectors characterized by sensitivity, spatial resolution 
properties, quantum detection efficiency, noise, and linearity of response.
This has improved diagnostic capability and relatively outweighs the potential reduction 
in limiting spatial resolution. DM technique offers many inherent advantages over the con-
ventional screen film-based technology [19, 20]. For instance, processing with digital sys-
tems increase dynamic range (two to four times the dynamic range of typical film-screen), 
improved quantum efficiency, signal-to-noise-signal, and storage and display mechanisms.
Moreover, DM detector provides features for automatic control of exposure factors of the 
image acquisition. This represents the spatial pattern of X-ray transmitted by the breast tis-
sue accurately. The use of computer-assisted image interpretation claimed to be helpful for 
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the physician. This may enhance different features such as computer-aided diagnosis, which 
may further improve the visibility of lesions and improve mammographic sensitivity [21]. 
Therefore, repeated exposures (which are sometimes, needed when using conventional mam-
mography) are not required and this may reduce the radiation dose. The advantage of digital 
imaging systems compared with film-screen imaging is the ability to manipulate and possibly 
enhance the displayed image. The breast dose levels required by current digital imaging sys-
tems are, in general, similar to those of a modern mammographic film-screen combination. 
However, developments in detector design and optimization of beam quality may eventually 
result in a reduction in radiation dose. With the use of DM, a number of image processing 
operations can be introduced to correct for spatial nonuniformities in detector responses. In 
addition, it is also possible to improve the effective spatial resolution of the detector. It also 
overcomes a number of limitations inherent in the screen-film image receptor used in conven-
tional mammography. Consequently, this improved the diagnostic image quality as well as 
reduced the doses to the breast tissues.
Furthermore, it does not need either cassettes or dark rooms or processors, and thus alleg-
edly saves space and time in archiving and retrieving DM images. However, DM requires 
large disk space for saving image data. Despite several advantages, DM does not yet reach 
the level of detail to replace screen film mammography. However, with continuous techni-
cal improvements of the digital system, this may be expected to change in the near future. 
Both conventional and DM systems suffer from substantial technical and clinical limitations. 
For instance, these systems are unreliable in imaging patients with dense parenchyma tissue 
especially in the younger female population due to more glandular tissue. Mammographic 
findings are nonspecific (cannot always differentiate benign from malignant disease) and 
often underestimate the size of the detected lesion. X-ray-based imaging is also not useful for 
breast diagnosis following surgery or radiotherapy, as the patient's breasts in these cases have 
architectural distortion.
Moreover, both the tube spectrum and the peak potential (KVp) are important parameters 
affecting the image quality in film-screen and digital mammography. Automatic selection 
of proper target/filter combination in modern mammography systems may be affected by 
improper KVp. In conventional devices, the user depends on central laboratory calibration 
and has no easy way to calibrate the instrument during use. It is worth mentioning that X-ray 
mammography is not always useful for nonpalpable tumors. Another group of women with a 
known family history of breast cancer was recommended not to repeat X-ray mammography. 
In other words, those close carrying a mutation in BRCA1 (human gene called breast cancer 1, 
early onset) or BRCA2 (breast cancer 2) genes. Those groups are at high genetic risk of cancer. 
Some even have opted for preventative bilateral mastectomy. It is preferred not to repeat scan 
in this group due to X-ray dose and thus, a more sensitive diagnostic test would be advis-
able. Once the diagnostic tests particularly X-ray mammography indicates or suspects breast 
cancer, breast biopsies are then performed. Breast biopsy is an invasive procedure used to 
remove tissue or cells from the breast for microscopic examination. This technique generally 
performed under local anesthesia. Several types of biopsy are available depending on loca-
tion, type, and size of lesion. Fine needle aspiration biopsy is performed by inserting a very 
thin needle to the lesion for taking a small sample of cells, fluid, or tissue. Core needle biopsy 
Breast Imaging8
is used with a large needle to remove a small cylindrical shape of tissue. Surgical biopsy 
involves removing part (incisional biopsy) or entire (excisional biopsy) lesion tissue.
In addition, a special wire localization technique may be used during surgery for deeply seated 
lesion. This technique usually performed under X-ray or ultrasound guidance. There are spe-
cial instruments and techniques that help to guide the needle biopsy. These include stereotactic 
biopsy with a 3D mammographic technique to find the exact location of breast lesion and vac-
uum-assisted biopsy using a tube to gently suck the breast lesion and a knife to remove tissue. 
This technique is much less traumatic than open biopsy. Moreover, a sentinel node (the first 
lymph node to receive drainage from a breast cancer cell) biopsy may often be used to deter-
mine whether cancer cells have spread to other tissue. In summary, invasive breast biopsies 
play an important role for evaluating breast cancer particularly nonpalpable lesions. These sur-
gical procedures are important for staging (see Table 2) and are considered the “gold standard” 
[17] to determine the presence or absence of breast cancer. However, invasive breast biopsy 
procedures are expensive, time consuming, and are often associated with emotional stress. It 
Stage Tumor size Lymph node involvement Metastasis
0 Carcinoma in situ N0 M0
I ≤2 cm N0 M0
IIA No evidence of tumor N1 M0
≤2 cm N1 M0
2–5 cm N0 M0
IIB 2–5 cm N1 M0
5 cm< N0 M0
IIIA No evidence of tumor N2 M0
≤2 cm N2 M0
2–5 cm N2 M0
5 cm< N1 M0
5 cm< N2 M0
IIIB Of any size N0 M0
Of any size N1 M0
Of any size N2 M0
IIIC Of any size N3 M0
IV Of any size Any N M1
Note: Beyond stage IIIB, the tumor is usually extended to either the skin or the chest wall and thus can be of any size. 
The N0 = no regional lymph node, N1 = metastasis in movable ipsilateral axillary lymph node(s), N2 = metastasis in 
ipsilateral axillary lymph node(s) fixed or matted, and N3 = metastasis in ipsilateral infraclavicular lymph node(s) or 
clinically apparent.
Table 2. The staging of breast cancer, adapted from Ref. [22].
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also causes scar and tissue distortion that complicate the future mammography. As a result, 
additional imaging tests are being used to reduce the trauma, cost, avoid, or minimize unneces-
sary invasive breast biopsies, and more importantly to further improve breast cancer diagnosis.
4.2. Complementary diagnostic techniques
From the previous discussion, it is clear that there are some clinical situations where there are 
significant limitations to use mammography in isolation. In such cases, there is a great need 
to use sensitive tests to achieve a high confidence and accurate diagnostic decision. The use 
of breast biopsies is necessary if breast cancer is indicated or suspected in such cases. Of the 
performed breast biopsies, ≈60–80% [17] are negative of breast cancer or have benign lesions. 
In these cases, breast biopsies are considered unnecessary. This has led many breast can-
cer experts to propose complementary imaging modalities to provide additional diagnostic 
information and reduce unnecessary breast biopsies. Over the last two decades, complemen-
tary diagnostic techniques such as ultrasonography (US), magnetic resonance imaging (MRI), 
and radionuclide breast imaging techniques have emerged as potential investigations for the 
detection and diagnosis of breast cancer. The radionuclide breast imaging technique, unlike 
X-ray mammography, is not affected by breast density. This has prompted a number of inves-
tigators to evaluate the feasibility of radionuclide breast imaging techniques in a screening 
context particularly for women with dense breast.
4.2.1. Ultrasonography
US uses high frequency acoustic waves that reflect at boundaries with different acoustic prop-
erties. It is a noninvasive technique, easily available, and relatively cheap. Breast US provides 
unique information in assessing both palpable and nonpalpable breast abnormalities. For 
instance, it clearly differentiates between solid masses and cystic lesions. It is considered to be 
useful in cancer staging, measuring tumor sizes, easy accessing lesions located in peripheries, 
and reducing the number of unnecessary biopsies. It allows accurate needle placement dur-
ing biopsy and is very useful for aspiration of cysts. The members of the European group for 
breast cancer screening recommended using US as a complementary method to X-ray mam-
mography. In addition, the use of high frequency transducers has improved spatial resolution 
and thus claimed to be useful in axillary node evaluation. However, breast US technique is 
time consuming and operator/observer dependent. It has also a number of other limitations 
that may be due to the overlapping in sonographic characteristics. For instance, it cannot 
detect calcifications (micro calcifications or macro calcifications) in ductal carcinoma in situ 
(DCIS). It could also miss solid lesions especially in a fatty breast and if detected cannot deter-
mine whether a solid mass is benign or malignant. For these reasons, US is not used in some 
institutions as a screening technique for asymptomatic breast cancer as it is difficult to ensure 
that the entire breast has been scanned.
4.2.2. Magnetic resonance imaging
Magnetic resonance imaging (MRI) images is created by the recording of signals generated 
after radio-frequency excitation of nuclear particles exposed to strong magnetic field. Breast 
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MRI is a nonionizing tomographic functional technique that may be used when the diag-
nosis is uncertain with mammography [23]. The technique is valuable for specific clinical 
indications such as patients with (1) axillary adenopathy (enlargement or inflammation of 
lymph gland), (2) possible tumor recurrence after surgery or radiotherapy, (3) lesions overly-
ing implants, or (4) those requiring staging of multi-focal carcinoma (two or more discrete 
lesions in one breast) [24]. Breast MRI with dedicated breast coil has excellent soft tissue reso-
lution that enhances the ability to both identify the location and in some cases determines the 
full extent of the lesion. The use of intravenous contrast agent, gadolinium, which accumu-
lates in tissues with a dense blood vessel network, also increases the sensitivity of breast MRI 
[16]. However, the reported specificity (ability to determine if lesion is benign or malignant) 
is 56–72% [24]. This technique has a limited application in patients with implanted metal 
devices or other metallic materials inside the body. In addition, several clinical limitations 
have been reported in the literature suggested not to use MRI in pre-menopausal women. For 
example, changes that do occur in the T
1
 value of the breast tissue during the menstrual cycle 
[24] mean that patients should be scanned between the 6th and 16th day of the cycle. In sum-
mary, researchers have concluded that breast MRI is very sensitive, but not very specific and 
thus, cannot be used alone to rule out cancer. MRI is limited by lack of availability and incon-
sistent quality, and the technique is too expensive for routine use in breast cancer screening 
in the general patient population.
4.2.3. Radionuclide breast imaging techniques
The need to improve breast cancer detection and to reduce unnecessary invasive breast biop-
sies has stimulated researchers to investigate functional imaging modalities. These techniques 
produce a range of different imaging approaches such as positron emission tomography 
(PET), single photon emission computed tomography (SPECT), planar imaging, and dedi-
cated imaging instrumentation with and without breast compression. These imaging tech-
niques of the breast potentially offer additional information in breast cancer diagnosis. This 
is because these imaging methods rely on the physiological and biochemical characteristics 
of a lesion. Thus, it is considered as the best hope to differentiate between benign/normal and 
malignant diseases. These functional techniques are also used to assess and monitor the effect 
of cancer prevention drugs. The current radionuclide imaging techniques used for breast 
tumor imaging are briefly discussed.
4.2.3.1. Positron emission mammography
In PET, a small amount of positron emitter radiotracer, 18F fluorodeoxyglucose (FDG), is 
administered intravenously to the patient [25]. It is then distributed in the body, and as it 
decays, the radionuclide emits a positron in any random direction. If the positron while trav-
elling interacts with an electron within the body, the two particles then annihilate and pro-
duce two γ-rays of 511 keV each. Either a whole body scanner or a breast-specific positron 
emission mammography (PEM) camera [26] is used to detect the two γ-rays in coincidence 
(two events that are detected within ≈12 ns). PEM is increasingly used in North America not 
only in cancer diagnosis but also in staging, planning, and monitoring anticancer therapy. 
This information can be helpful in eliminating unnecessary axillary dissection [27], biopsies, 
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and in determining the appropriate treatment. The diagnosis of viable tumor tissue follow-
ing chemotherapy is another application of PET [28, 29]. Imaging with 18F-FDG has shown 
considerable promise in breast cancer imaging, but the exact role is still in evolution. Wahl 
[30] recommended that it is best applied to solve difficult clinical cases in specific patients 
rather than routinely. There are at least four reasons that limit the wide use of PEM for routine 
cancer diagnosis. The first one is the high cost (over £2 million) of PET coincidence imaging 
equipment, i.e., cyclotron, scanner, and radiochemistry facility [25]. The second one is the dif-
ficulty of producing and labeling the short half-life PET radionuclides [21]. The third reason is 
the lack of medical centers with the required experience to develop more advanced methodol-
ogy appropriate for breast oncology. In particular, more data is still needed concerning the 
metabolism of different PET radiopharmaceuticals in breast tumors. The final reason is the 
lack of oncologists with a high knowledge of PET methodology [30].
4.2.3.2. Scintimammography
Scintimammography (SM) is a promising noninvasive functional imaging technique. It has 
been proposed to complement X-ray mammography and to improve patient selection for 
biopsy. This single photon imaging of the breast involves injecting the patient in the arm 
vein with a small amount (555–740 MBq [31]) of radiopharmaceutical. The most commonly 
used radiopharmaceutical for SM is 99mTc labeled sestamibi. After injection, the radiophar-
maceutical distributes in the breast tissue as well as in other body organs. It accumulates 
more in the target object (breast lesion) with uptake ratio nearly 9:1 tumor-to-background-
ratio (TBR) [32]. A standard full-size clinical gamma camera is then used to scan the patient 
and thus measure the 3D distribution of the radioactivity. SM imaging using full size clinical 
γ-camera includes a range of different imaging approaches such as planar (2D) imaging or 
SPECT technique. The latter technique gives a 3D image but is not widely used because it is 
difficult to accurately localize the lesion [33]. In contrast, planar SM is the technique that is 
more widely used in clinical practice because it provides better lesion localization particularly 
the prone images with lateral views [33]. In this case, the gamma camera is usually equipped 
with a low energy high resolution (LEHR) parallel-hole collimator and two views (prone and 
supine) are taken, to the diagnosed breast. Since the energy imaged is 140 keV representing 
the photopeak, 20% energy window (symmetric ±10%) is often used and thus, centered over 
the photopeak. The main clinical applications of planar SM imaging are summarized here 
and the details are found in literatures [33–39]. In brief, SM with a general purpose γ-camera 
introduced to evaluate patients with dense breast tissue and prior to breast biopsy [34]. The 
technique is considered valuable for many clinical applications such as evaluating the axillary 
lymph nodes, investigating patients with micro calcifications [35], assessing multi-focal and 
multi-centric breast cancer diseases [36]. It is also useful for imaging patients following sur-
gery, chemotherapy, hormonal replacement therapy, and radiotherapy as well as for patients 
with breast implants [33]. The technique may also assist in the differentiation of benign and 
malignant breast abnormalities by measuring the radiotracer uptake in the lesion as com-
pared with surrounding breast tissue. Studies such as Refs. [37, 38] suggested that SM may 
be used as a second-line diagnostic test in cases where the sensitivity of mammography is 
decreased or there is a doubt about the presence of a lesion.
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In summary, SM using conventional γ-camera is considered as a useful complementary imag-
ing modality to aid the diagnosis and the detection of breast cancer [39]. It may also help to 
assess patients recommended for biopsy and this may reduce the number of unnecessary or 
benign breast biopsies. However, the major drawback of the current standard clinical gamma 
camera SM imaging systems is the use of mechanical collimator. This causes the camera imag-
ing system to utilize a very small fraction, ∼0.01%, of the total number of the emitted photons. 
This limits the statistics and hence the quality and diagnostic value of the observed images. 
The collimator sensitivity and resolution are a trade-off and the camera is also limited by its 
intrinsic spatial resolution. As a result, these factors make it difficult to practically image cases 
of smaller, nonpalpable lesions (<1 cm) that may be deep seated or those close to the chest 
wall. These have stimulated the development of newly dedicated (breast specific) instrumen-
tations that used for breast tumor imaging applications.
4.2.3.3. Dedicated breast cameras
Recent years have seen considerable interest by scientists in developing new compact medi-
cal imaging detectors. These instruments proposed for different clinical applications with the 
aim to improve image quality by building cameras of suitable size and shape for the part of 
the body under investigation. Among these designed detectors is the small-dedicated gamma 
camera for functional breast tumor imaging. The justification for this development is that a 
standard full size clinical gamma camera designed for whole body imaging and thus, is not 
been optimized for breast tumor imaging. In other words, there are a number of shortcom-
ings with such general purpose gamma camera such as the limiting sensitivity. On average 
(50% [40]) for lesions <1 cm such as DCIS particularly, the medially located tumors. In addi-
tion, several studies [41–52] have pointed out that due to the large FoV of the camera and the 
bulky collimators, it is difficult to position the camera close to the breast, and thus, imaging 
breast tissue adjacent to the chest wall may not be possible. This may, ultimately, decrease the 
spatial resolution of the camera imaging system and thus affect the diagnostic value of the 
test in detecting such a small lesion size. To overcome some of the limitations offered by con-
ventional gamma camera on breast imaging, Gupta et al. [41] reported the first preliminary 
clinical data that performed with breast-specific detectors and then compare it with the data 
obtained from standard full-size camera. A limited number of patients were investigated in 
this study but interestingly reported a higher sensitivity for the dedicated camera. Following 
this and due to the large research activities, new generation of detectors have been designed 
and developed for breast tumor imaging. For instance, the position-sensitive photo-multiplier 
tubes (PSPMT), semiconductor arrays, and scintillation crystals are coupled to an array of 
solid-state photodetectors. Table 3 summarizes the features and the physical parameters of 
some of the currently under investigation and the commercially available dedicated breast 
camera. In general, these small FoV detectors have led to the improvement of the overall spa-
tial resolution of such imaging system.
The commercially available dedicated breast camera has two detectors and is designed and 
optimized to image only the breasts. It possesses a high intrinsic spatial resolution and the cam-
era is also equipped with ultra-high resolution parallel-hole collimator and thus,  optimized 
Detection and Diagnosis of Breast Diseases
http://dx.doi.org/10.5772/intechopen.69898
13
for high-resolution SM. The main advantage of such cameras is the ability to separate the breast 
from the chest wall by positioning the camera close to the breast. Thus, the camera can be used 
in areas with limited space (e.g., medial view can be possible), where the use of a full-sized 
camera is impractical or impossible. The use of moderate breast compression capabilities may 
improve both the signal-to-noise ratio (SNR) and the spatial resolution [42] and thus increase 
the sensitivity for detecting smaller lesions. The proposed clinical indications for such dedi-
cated cameras are similar to the full size clinical gamma camera SM. There are some recent 
clinical studies associated with using these dedicated gamma cameras. For instance, a clini-
cal preliminary study by Brem et al. [43, 44] using dedicated breast camera demonstrated a 
slight improvement in resolution and tumor sensitivity particularly for lesions ≤1 cm. Rhodes 
et al. reported [45] on SM, performed on 40 women with small mammographic abnormalities 
(<2 cm) scheduled to undergo biopsy. The SM examination identified (33/36) malignant lesions 
confirmed at biopsy. The authors concluded that this preliminary study suggested an impor-
tant role for the dedicated SM camera in women with dense breasts.
In another study, Brem et al. [46] evaluated 94 women (median age 55 years) who presented 
with normal mammographic and physical examination results but all subjects were consid-
ered at high risk of developing breast cancer. Of these women, 35 had a history of previous 
breast carcinoma or atypical ductal hyperplasia. The authors concluded that with this cam-
era, they could depict small (8–9 mm) nonpalpable lesions in women at a high risk of breast 
cancer. In summary, while these studies using breast-specific cameras are promising, all are 
considered preliminary in nature because they are based on very few cases. Additional stud-
ies with a larger sample size are needed to accurately assess and reach scientific conclusions 
concerning these proposed cameras. They also need to be cost competitive with the general 
Cameras and study 
(reference)
Crystal sizes  
(mm3)
FoV sizes (cm2) Intrinsic resolution 
(mm)
Spatial resolution 
(mm)
Energy resolution 
(%)
CsI(TI) [47] 2 × 2 × 3 10 × 10 2 9 n/a
CsI(Si) [49] 3 ×3 × 6 21 × 21 3 6.5 n/a
NaI(TI) [50] 3 ×3 × 6 15 × 20 3 6.3 10%
LumaGEM
Nal(TI) [42, 50]
2 ×2 × 6 12.8 × 12.8 2.2 3.4 10%
LumaGEM
32000S/12K2
(CZT) [51]
2.5 ×2.5 × 5 16 × 20 1.58 2.5 6%
LumaGEM (CsI)
5600 crystal [52]
3 × 3× 6 10 × 10 1.7 n/a n/a
All cameras are based on PSPMT(s) principle. The CZT detector array absorbs the γ-rays directly and converts their 
energy into electrical signal without the conversion to visible light as in the case with a scintillation detector. The spatial 
resolution is measured with general purpose collimator at 10 cm distance except the LumaGEM cameras that based on 
ultra-high resolution collimators.
Note: n/a, not available.
Table 3. Physical characteristics and specifications of dedicated gamma cameras proposed for scintimammography.
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purpose gamma cameras in order to be widely used in breast tumor imaging applications. 
In addition, the smallest lesion sizes that can be detected with these cameras claimed to be 
3–3.3 mm [47] compared to 4–5 mm [48] with conventional camera. However, the evidence 
published to date did not demonstrate a statistically significant difference in lesion detection. 
The spatial resolution of these proposed cameras may further improve by increasing the pixel 
size but there are practical limitations in the development of cameras with small pixel sizes, 
including cost and detector design. More importantly, due to the use of collimator, these dedi-
cated cameras suffer from low detection efficiency.
4.3. Summary of the role of different imaging modalities
In many centers, the current evaluation and primary diagnosis of breast are based on com-
bination of physical examination, mammography, and breast biopsy. Mammography repre-
sents a significant contribution and remains the gold standard for breast tumor imaging. This 
is because mammography is relatively simple, cost-effective, and relatively, highly sensitive. 
However, in many clinical cases, mammography may be nonspecific and lesions may not 
be detected. This is because the breast lesion can be indistinguishable from normal breast 
tissue or obscured by the dense parenchyma. Mammography is also not reliable following 
radiation therapy, surgery, and hormonal replacement therapy. Consequently, breast biop-
sies are used for many cases as a second-line diagnostic test to evaluate a suspicious lesion. 
Unfortunately, many breast biopsies are performed on normal patients, which results in high 
cost and patient’s stress. Thus, other noninvasive imaging techniques are needed and can be 
used as complementary functional methods to minimize unnecessary breast biopsies.
MRI and US are adjunctive imaging techniques to mammography. Breast US is relatively 
inexpensive and is currently the commonest complementary method. This technique is also 
useful particularly when there is a cyst in the breast, but has lower accuracy in solid lesions. 
Breast MRI with contrast is a sensitive and relatively specific technique for some certain indi-
cations but are too expensive to be used routinely. Both MRI and US are useful tools in breast 
diagnosis, in particular for solving problems in selected applications. For the aforementioned 
reasons, the use of complementary imaging techniques, to aid in the diagnosis, is necessary. 
Thus, additional imaging methods are needed for investigation, detection, and diagnosis of 
breast cancer. Functional breast γ-ray imaging techniques have aided breast cancer diagnosis.
Among the currently used techniques are planar SM with 99mTc labeled sestamibi and PET 
with 18F-FDG. Both radionuclide techniques have been emerged as potential investigation for 
the detection and diagnosis of breast cancer. Consequently, it is increasingly used particu-
larly for imaging patients with dense breasts. Having discussed commercial imaging meth-
odologies, various weaknesses in each approach has led to the need for new complimentary 
imaging methods. Of these approaches, SM is one of the most promising approach. The cur-
rent research in this area is focusing on dedicated collimator-based cameras. These dedicated 
cameras also suffer from low detection efficiency. In addition, this is an unattractive option 
for many health providers, due to limited clinical applications of such an imaging system. 
This provides the motivation for investigating the application of collimator-less method in 
breast tumor imaging. A gamma camera, employing a low energy high resolution (LEHR) 
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 parallel-hole collimator is used, to generate an image of the resulting radionuclide distribu-
tion. The LEHR collimator geometrically selects γ-photons from a predetermined direction 
and as a result, a very small fraction of the total emitted photons reaches the detector. Thus, 
this limits the detection efficiency and spatial resolution of the observed image–collimator are 
trade-off.
Factors like these have generated massive research aimed to improve the accuracy and 
efficiency of the current SM imaging systems and reduce the overall costs of breast surgi-
cal biopsies procedures but without the need for the new dedicated camera instrumentation 
development. This is one of the primary motivations to carry out research using a simple 
coded aperture (CA) mask, instead of a collimator, coupled to a standard clinical gamma 
camera for breast tumor imaging without the need for a new dedicated camera instrumenta-
tion development. This is particularly attractive at general hospital level, where the cost of 
running an additional dedicated imaging system may be prohibitive. In addition, the smallest 
lesion sizes that can be detected with dedicated cameras claimed to be 4–5 mm compared to 
8–10 mm with conventional camera. The spatial resolution of these proposed cameras may 
further improve by increasing the pixel size, but there are practical limitations in the develop-
ment of cameras with small pixel sizes, including cost and detector design. CA imaging as 
originally developed for astronomical applications is well suited for detecting faint pseudo-
point like objects in a nonzero background. Thus, it appears to be well matched to the imaging 
objectives in SM. While related prior work has also considered, this approach is characterized 
by gross simplifications in terms of clinical reality [53, 54].
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